Term
|
Definition
Inhibits carbonic anhydrase |
|
|
Term
|
Definition
reduces reabsorption of bicarb in the proximal tubule, causing self-limited diuresis, hyperchloremic metabolic acidosis reduces body pH, reduced intraocular pressure |
|
|
Term
Acetazolamide - clinical applications? |
|
Definition
Glaucoma, mountain sickness, edema with alkalosis |
|
|
Term
Acetazolamide - kinetics, tox? |
|
Definition
oral and topical, 8-12 hr DOA, tox - metabolic acidosis, rental stones, hyperammonia in cirrhotics |
|
|
Term
What kind of drugs are brinzolamide and dorzolamide? What are they used for? |
|
Definition
carbonic anhydrase inhibitors, topical for glaucoma |
|
|
Term
|
Definition
inhibits the Na/K/2Cl transporter in the thick ascending limb |
|
|
Term
|
Definition
Marked increase in NaCl excretion, some K wasting, hypokalemic metabolic acidosis, increased URINE Ca and Mg |
|
|
Term
Furosemide - clinical applications? |
|
Definition
Pulmonary edema, peripheral edema, hypertension, acute hypercalcemia or hyperkalemia, acute renal failure, anion overdose |
|
|
Term
Furosemide - kinetics, tox? |
|
Definition
Oral and parenteral, 2-4hr DOA, ototoxicity, hypovolemia, K wasting, hyperuricemia, hypomagnesemia |
|
|
Term
What are bumetanide and torsemide? |
|
Definition
Sulfonamide loop agents like furosemide |
|
|
Term
|
Definition
Not a sulfonamide but has typical loop activity and some uricosuric action |
|
|
Term
|
Definition
Inhibition of the Na/Cl transporter in the distal convoluted tubule |
|
|
Term
|
Definition
Modest increase in NaCl excretion, some K wasting, hypokalemic metabolic alkalosis, decreased urine Ca |
|
|
Term
HCTZ - clinical applications? |
|
Definition
HTN, mild heart failure, nephrolithiasis, nephrogenic diabetes insipidus |
|
|
Term
|
Definition
Oral, duration 8-12 hr, hypokalemic metabolic acidosis, hyperuricemia, hyperglycemia, hyponatremia |
|
|
Term
Metazoline is popular for use WITH what types of drugs? |
|
Definition
loop agents, for synergistic effect |
|
|
Term
What is the only parenteral thiazide available? |
|
Definition
|
|
Term
|
Definition
pharmacologist antagonist of aldosterone, weak antagonism of androgen receptors |
|
|
Term
Spironolactone - effects? |
|
Definition
Reduces Na retention and K wasting, poorly understood antagonism of aldosterone in heart and vessels |
|
|
Term
Spironolactone - clinical applications? |
|
Definition
aldosteronism from any cause, hypokalemia occurring from other diuretics, post-MI |
|
|
Term
Spironolactone - kinetics, tox? |
|
Definition
Slow onset and offset, 24-28 hr duration, hyperkalemia, gynecomastia, additive interaction with other K-sparing drugs |
|
|
Term
|
Definition
Blocks epithelial sodium channels in collecting tubules |
|
|
Term
|
Definition
Reduces Na retention and K wasting, increases lithium clearance |
|
|
Term
Amiloride - clinical applications? |
|
Definition
hypokalemia occurring from other diuretics, reduces lithium-induced polyuria |
|
|
Term
Amiloride - kinetics, tox? |
|
Definition
orally active, duration 24h, hyperkalemic metabolic acidosis |
|
|
Term
|
Definition
Like spironolactone, more selective for aldosterone receptor |
|
|
Term
|
Definition
|
|
Term
|
Definition
mechanism like amiloride, much less potent and more toxic |
|
|
Term
|
Definition
mechanism like amiloride, much less potent and more toxic |
|
|
Term
|
Definition
physical osmotic effect, contained in the vascular compartment |
|
|
Term
|
Definition
marked increase in urine flow, reduced brain volume, decreased IOP, initial hyponatremia, then hypernatremia |
|
|
Term
Mannitol - clinical applications? |
|
Definition
renal failure due to increased solute load (rhabdo, chemo), increased ICP, glaucoma |
|
|
Term
Mannitol - kinetics, tox? |
|
Definition
|
|
Term
|
Definition
Antagonist at V1a and V2 ADH receptors |
|
|
Term
|
Definition
Reduces water reabsorption, increases plasma Na concentration |
|
|
Term
Conivaptan - clinical applications? |
|
Definition
|
|
Term
Conivaptan - kinetics, tox? |
|
Definition
IV only, infusion site reactions |
|
|